Research Alerts — Clinical Trial Evidence
Dated updates on peptide clinical trials, published results, and remaining evidence gaps, with links to original reports and registries.
Reviewed
Trial registration, trial completion, a sponsor announcement, and a published result are different milestones. This page records selected changes reviewed on September 30, 2026. Open each linked registry record for its current status; registry entries can change after this review.
Retatrutide: phase 3 diabetes result, obesity results still separate
The published TRANSCEND-T2D-1 phase 3 trial randomized 537 adults with type 2 diabetes inadequately controlled by diet and exercise. At week 40, the treatment-regimen estimand found HbA1c changes of −1.69%, −1.86%, and −1.94% in the 4, 9, and 12 mg groups versus −0.81% with placebo. Corresponding body-weight changes were −11.5%, −13.9%, and −15.3% versus −2.6%. These are diabetes-trial results, not a completed head-to-head obesity comparison with another drug. Retatrutide remained investigational in the report.
TRIUMPH-1 (NCT05929066) was marked completed in the registry at this review; that status does not itself provide published efficacy results. The TRIUMPH program design report describes TRIUMPH-3 as a weight-management study in a cardiovascular-disease population. It is not a MASH trial.
The older 48-week phase 2 obesity trial reported −24.2% mean weight change in its 12 mg group versus −2.1% with placebo. The dose, population, phase, and duration must accompany that number. It cannot be ranked against separate trials of approved products.
CagriSema: REDEFINE reports are published
The combination of cagrilintide and semaglutide remains a distinct investigational product. REDEFINE 1 and REDEFINE 2 were published in 2025; their initial results are no longer “expected.” In REDEFINE 2, adults with overweight or obesity and type 2 diabetes had mean weight change of −13.7% with the combination versus −3.4% with placebo at week 68. The published studies do not, by themselves, establish FDA approval.
For a structured comparison with approved incretin products, see the GLP-1 and amylin comparison.
New amylin and dual-incretin programs
Four investigational molecules now have original human reports suitable for dedicated profiles:
| Molecule | Published human evidence | Main limit |
|---|---|---|
| Zenagamtide (amycretin) | Injectable phase 1b/2a randomized study | Small early-phase study; oral and injectable evidence must be kept separate. |
| Eloralintide | Phase 1 proof-of-concept study | Twelve-week cohort findings; long-term safety and efficacy are unknown. |
| VK2735 | VENTURE phase 2, 13-week study | Dose-ranging, short follow-up; not a comparison against approved products. |
| Petrelintide | Two randomized phase 1 studies | Early-phase pharmacology and weight signal; later sponsor topline results need full publication. |
BPC-157: a registry record is not a clinical benefit
BPC-157 continues to have a large preclinical literature and limited published human efficacy evidence. A registered phase 2 hamstring-strain study, NCT07437547, had no results posted at this review. A trial's presence in a registry does not demonstrate efficacy, safety, or an approved indication. See the BPC-157 evidence guide for the distinction between models and human outcomes.
How to read an alert
Check the exact molecule and formulation, the population, phase, comparator, endpoint, follow-up period, and publication status. A ClinicalTrials.gov status is maintained by the responsible party and can change. For FDA approval or safety decisions, use the product record rather than inferring approval from a trial or press release.